Roivant Sciences (NASDAQ:ROIV) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Roivant Sciences (NASDAQ:ROIV - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04, Zacks reports. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%.

Roivant Sciences Stock Up 0.1 %

Roivant Sciences stock traded up $0.01 during midday trading on Thursday, hitting $10.45. 4,834,629 shares of the stock were exchanged, compared to its average volume of 4,322,273. Roivant Sciences has a 52-week low of $9.76 and a 52-week high of $13.06. The stock has a market capitalization of $7.61 billion, a price-to-earnings ratio of 1.85 and a beta of 1.25. The business's 50-day moving average price is $11.41 and its 200-day moving average price is $11.59.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Thursday, January 30th. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of "Buy" and an average price target of $17.93.

Insider Buying and Selling

In other Roivant Sciences news, CIO Mayukh Sukhatme sold 185,946 shares of the business's stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $12.00, for a total value of $2,231,352.00. Following the transaction, the executive now directly owns 18,836,547 shares in the company, valued at $226,038,564. The trade was a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 100,000 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the completion of the transaction, the chief operating officer now owns 732,294 shares in the company, valued at approximately $8,260,276.32. The trade was a 12.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,942,629 shares of company stock worth $23,034,486. 7.90% of the stock is owned by insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.